Oncology Central

Oncolytic virotherapy before surgery sensitizes TNBC to checkpoint therapy

Researchers have demonstrated that neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer (TNBC) to immune checkpoint therapy. The findings were recently published in Science Translational Medicine.

TNBC is a notoriously aggressive and difficult-to-treat type of breast cancer for which treatment options are few and associated with severe toxicities. Utilizing a therapeutic mouse model that mimics the metastatic spread of breast cancer after surgery, researchers have demonstrated that oncolytic virus therapy in combination with immune checkpoint blockade cured 60–90% of the mice, compared

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.